Influenza mimetic protein–polymer nanoparticles as antigen delivery vehicles to dendritic cells for cancer immunotherapy

Nanoscale ◽  
2019 ◽  
Vol 11 (29) ◽  
pp. 13878-13884 ◽  
Author(s):  
Chaeyeon Lee ◽  
Leeja Jose ◽  
KyuHwan Shim ◽  
Seong Soo A. An ◽  
Sunah Jang ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Tumor Antigen ◽  
Polymer Nanoparticles ◽  
Antigen Delivery ◽  
Protein Polymer ◽  
Delivery Vehicles

We introduce virus-mimetic polymer nanoparticles as tumor antigen delivery vehicles to induce adjuvant-free cancer Ag specific-immune responses.

scholarly journals Induction of CD4+ T cell–dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells

2002 ◽  
Vol 109 (11) ◽  
pp. 1463-1470 ◽  
Author(s):  
Helen Y. Wang ◽  
Tihui Fu ◽  
Gang Wang ◽  
Gang Zeng ◽  
Donna M. Perry-Lalley ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Tumor Antigen ◽  
Antitumor Immunity ◽  
Cd4 T Cell ◽  
Antigen Delivery

Polyelectrolyte Microcapsules as Antigen Delivery Vehicles To Dendritic Cells: Uptake, Processing, and Cross-Presentation of Encapsulated Antigens

2009 ◽  
Vol 121 (45) ◽  
pp. 8637-8641 ◽  
Author(s):  
Stefaan De Koker ◽  
Bruno G. De Geest ◽  
Satwinder K. Singh ◽  
Riet De Rycke ◽  
Thomas Naessens ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Antigen Delivery ◽  
Cross Presentation ◽  
Polyelectrolyte Microcapsules ◽  
Delivery Vehicles

scholarly journals Antigen Delivery to CD11c+CD8− Dendritic Cells Induces Protective Immune Responses against Experimental Melanoma in Mice In Vivo

2014 ◽  
Vol 192 (12) ◽  
pp. 5830-5838 ◽  
Author(s):  
Kirsten Neubert ◽  
Christian H. K. Lehmann ◽  
Lukas Heger ◽  
Anna Baranska ◽  
Anna Maria Staedtler ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Immune Responses ◽  
Antigen Delivery

scholarly journals Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling

2020 ◽  
Vol 217 (5) ◽  
Author(s):  
Yaoyao Shi ◽  
Wenxin Zheng ◽  
Kaiting Yang ◽  
Katharine G. Harris ◽  
Kaiyuan Ni ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Tumor Microenvironment ◽  
Gut Microbiota ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Intestinal Microbiota ◽  
Local Delivery ◽  
Host Immunity ◽  
Tumor Tissues ◽  
Gut Immunity

Most studies focus on how intestinal microbiota influence cancer immunotherapy through activating gut immunity. However, immunotherapies related to innate responses such as CD47 blockade rely on the rapid immune responses within the tumor microenvironment. Using one defined anaerobic gut microbiota to track whether microbiota interact with host immunity, we observed that Bifidobacterium facilitates local anti-CD47 immunotherapy on tumor tissues through the capacity to accumulate within the tumor microenvironment. Systemic administration of Bifidobacterium leads to its accumulation within the tumor and converts the nonresponder mice into responders to anti-CD47 immunotherapy in a stimulator of interferon genes (STING)– and interferon-dependent fashion. Local delivery of Bifidobacterium potently stimulates STING signaling and increases cross-priming of dendritic cells after anti-CD47 treatment. Our study identifies the mechanism by which gut microbiota preferentially colonize in tumor sites and facilitate immunotherapy via STING signaling.

Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response

Nanomedicine ◽  
2020 ◽  
Vol 15 (17) ◽  
pp. 1641-1652
Author(s):  
Wen Liu ◽  
Yuki Takahashi ◽  
Masaki Morishita ◽  
Makiya Nishikawa ◽  
Yoshinobu Takakura
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Dendritic Cells ◽  
Immune Responses ◽  
Antigen Presentation ◽  
Extracellular Vesicles ◽  
Tumor Antigen ◽  
Tumor Antigens ◽  
Cd40 Ligand ◽  
Further Development

Aim: Tumor-derived small extracellular vesicles (TEVs) are considered for use in inducing tumor antigen-specific immune responses as they contain tumor antigens. The delivery of tumor antigens to the antigen presentation cells (especially dendritic cells [DCs]), and the activation of DCs are the main challenges of TEV therapy. Materials & methods: TEVs were modified with CD40 ligand (CD40L), which can target CD40 expressed on the surface of DCs and can activate them via CD40L-CD40 interactions. Results: It was found that CD40L-TEVs were efficiently taken up by DCs and also activated them. Moreover, tumor antigens were efficiently presented to the T cells by DCs treated with CD40L-TEVs. Conclusion: This study proved that CD40L-modification of TEVs will be helpful for further development of TEV-based tumor vaccination.

scholarly journals Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Stefanie K. Wculek ◽  
Joaquín Amores-Iniesta ◽  
Ruth Conde-Garrosa ◽  
Sofía C. Khouili ◽  
Ignacio Melero ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Cancer Immunotherapy ◽  
Tumor Antigen ◽  
Conventional Type

Polyelectrolyte Microcapsules as Antigen Delivery Vehicles To Dendritic Cells: Uptake, Processing, and Cross-Presentation of Encapsulated Antigens

2009 ◽  
Vol 48 (45) ◽  
pp. 8485-8489 ◽  
Author(s):  
Stefaan De Koker ◽  
Bruno G. De Geest ◽  
Satwinder K. Singh ◽  
Riet De Rycke ◽  
Thomas Naessens ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Antigen Delivery ◽  
Cross Presentation ◽  
Polyelectrolyte Microcapsules ◽  
Delivery Vehicles

RNA-loaded dendritic cells: more than a tour de force in cancer therapeutics

Immunotherapy ◽  
2019 ◽  
Vol 11 (13) ◽  
pp. 1129-1147
Author(s):  
Aishwarya Joshi ◽  
Nikunj Tandel ◽  
Priyanka Tyagi ◽  
Sarat K Dalai ◽  
Prakash S Bisen ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Immune Responses ◽  
Conventional Treatment ◽  
Treatment Options ◽  
Cancer Therapeutics ◽  
Therapeutic Strategies ◽  
Vital Role ◽  
Delivery Vehicles ◽  
Immune Competency ◽  
Potential Use

A wide array of therapeutic strategies has been implemented against cancers, yet their clinical benefit is limited. The lack of clinical efficacy of the conventional treatment options might be due to the inept immune competency of the patients. Dendritic cells (DCs) have a vital role in initiating and directing immune responses and have been frequently used as delivery vehicles in clinical research. The recent clinical data suggest the potential use of DCs pulsed with nucleic acid, especially with RNA holds a great potential as an immunotherapeutic measure with compare to other cancer therapeutics. This review mainly deals with the DCs and their role in transfection with RNA in cancer immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document